Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDXS Codexis	$2.35 +0.9%	$2.40	$1.90 ▼ $6.08	$194.69M	2.56	698,162 shs	1.33 million shs
MYGN Myriad Genetics	$4.16 -3.9%	$6.80	$3.81 ▼ $29.30	$383.46M	2.01	1.16 million shs	1.66 million shs
RIGL Rigel Pharmaceuticals	$19.53 +1.8%	$18.36	$7.48 ▼ $29.82	$342.96M	1.34	217,785 shs	122,629 shs
ZBIO Zenas Biopharma	$10.00 +8.3%	$9.31	$5.83 ▼ $26.25	$418.34M	N/A	181,781 shs	210,381 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDXS Codexis	-8.63%	-0.43%	0.00%	-40.71%	-26.03%
MYGN Myriad Genetics	+4.34%	+6.39%	-42.27%	-60.89%	-81.43%
RIGL Rigel Pharmaceuticals	-2.19%	-8.36%	-1.13%	-11.89%	+106.03%
ZBIO Zenas Biopharma	-12.59%	-15.63%	-7.24%	+922,999,900.00%	+922,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDXS Codexis	3.5468 of 5 stars	3.3	1.0	0.0	2.5	3.6	1.7	0.6
MYGN Myriad Genetics	3.7857 of 5 stars	4.0	1.0	0.0	4.1	1.1	1.7	0.6
RIGL Rigel Pharmaceuticals	2.6845 of 5 stars	3.2	1.0	0.0	0.0	3.3	1.7	1.9
ZBIO Zenas Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDXS Codexis	2.67	Moderate Buy	$8.00	240.43% Upside
MYGN Myriad Genetics	2.06	Hold	$14.79	255.43% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	86.38% Upside
ZBIO Zenas Biopharma	3.00	Buy	$36.67	266.67% Upside

Current Analyst Ratings Breakdown

Latest CDXS, MYGN, ZBIO, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/16/2025	ZBIO Zenas Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/15/2025	ZBIO Zenas Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$35.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00
5/7/2025	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$22.00 ➝ $6.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDXS Codexis	$49.82M	3.91	N/A	N/A	$1.24 per share	1.90
MYGN Myriad Genetics	$831.30M	0.46	N/A	N/A	$9.53 per share	0.44
RIGL Rigel Pharmaceuticals	$203.08M	1.72	N/A	N/A	($1.64) per share	-11.91
ZBIO Zenas Biopharma	$15M	27.89	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDXS Codexis	-$76.24M	-$0.99	N/A	N/A	N/A	-96.35%	-71.56%	-38.00%	8/14/2025 (Estimated)
MYGN Myriad Genetics	-$263.30M	-$1.12	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	8/5/2025 (Estimated)
RIGL Rigel Pharmaceuticals	-$25.09M	$2.07	139.51	18.60	N/A	2.46%	-14.80%	3.03%	8/5/2025 (Estimated)
ZBIO Zenas Biopharma	N/A	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest CDXS, MYGN, ZBIO, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ZBIO Zenas Biopharma	-$1.15	-$0.80	+$0.35	-$0.80	$5.00 million	$10.00 million
5/14/2025	Q1 2025	CDXS Codexis	-$0.20	-$0.25	-$0.05	-$0.25	$10.38 million	$7.54 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million
3/4/2025	Q4 2024	RIGL Rigel Pharmaceuticals	$0.30	$0.80	+$0.50	$0.80	$57.59 million	$57.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDXS Codexis	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas Biopharma	$0.05	0.48%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDXS Codexis	0.39	3.21	3.15
MYGN Myriad Genetics	0.05	1.90	1.73
RIGL Rigel Pharmaceuticals	N/A	1.96	1.87
ZBIO Zenas Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDXS Codexis	78.54%
MYGN Myriad Genetics	99.02%
RIGL Rigel Pharmaceuticals	66.23%
ZBIO Zenas Biopharma	N/A

Insider Ownership

Company	Insider Ownership
CDXS Codexis	2.10%
MYGN Myriad Genetics	2.40%
RIGL Rigel Pharmaceuticals	9.48%
ZBIO Zenas Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDXS Codexis	250	82.85 million	79.67 million	Optionable
MYGN Myriad Genetics	2,600	92.18 million	89.12 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.02 million	Optionable
ZBIO Zenas Biopharma	N/A	41.83 million	N/A	N/A

CDXS, MYGN, ZBIO, and RIGL Headlines

Recent News About These Companies

ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

May 29 at 7:16 PM | globenewswire.com

Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Shareholders of Class Action Lawsuit and June 16, 2025 Deadline

May 29 at 2:30 PM | accessnewswire.com

ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

May 29 at 2:15 PM | globenewswire.com

The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc. (ZBIO) of a Class Action Lawsuit and an Upcoming Deadline

May 29 at 12:24 PM | globenewswire.com

Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO) Investors - Contact Levi & Korsinsky Before June 16, 2025

May 29 at 11:00 AM | accessnewswire.com

Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025

May 29 at 7:25 AM | accessnewswire.com

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

May 29 at 7:05 AM | globenewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

May 29 at 7:00 AM | accessnewswire.com

Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO

May 29 at 5:45 AM | prnewswire.com

Investors in Zenas BioPharma, Inc. (ZBIO): Protect Your Rights - Contact Levi & Korsinsky Before June 16, 2025

May 28 at 4:30 PM | accessnewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 28 at 4:00 PM | globenewswire.com

ZBIO DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - ZBIO

May 28 at 3:52 PM | accessnewswire.com

Class Action Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 Deadline

May 28 at 2:25 PM | accessnewswire.com

June 16, 2025 Deadline Approaching: Join Class Action Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky

May 28 at 11:45 AM | accessnewswire.com

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 28 at 11:25 AM | prnewswire.com

ZBIO ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Zenas BioPharma, Inc. - June 16, 2025 Deadline

May 28 at 10:00 AM | accessnewswire.com

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

May 28 at 9:31 AM | prnewswire.com

Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Shareholders of Class Action Lawsuit and June 16, 2025 Deadline

May 28 at 7:15 AM | accessnewswire.com

ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

May 28 at 7:00 AM | accessnewswire.com

Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors – Lead Plaintiff Deadline on June 16, 2025

May 27 at 9:15 PM | accessnewswire.com

What is Wedbush's Estimate for Zenas Biopharma Q2 Earnings?

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS, MYGN, ZBIO, and RIGL Company Descriptions

Codexis NASDAQ:CDXS

$2.35 +0.02 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 +0.02 (+0.81%)

As of 07:19 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Myriad Genetics NASDAQ:MYGN

$4.16 -0.17 (-3.93%)

Closing price 04:00 PM Eastern

Extended Trading

$4.17 +0.01 (+0.14%)

As of 07:19 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Rigel Pharmaceuticals NASDAQ:RIGL

$19.53 +0.34 (+1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$19.74 +0.22 (+1.10%)

As of 07:14 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Zenas Biopharma NASDAQ:ZBIO

$10.00 +0.77 (+8.34%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time